Negamycin analogue with readthrough-promoting activity as a potential drug candidate for Duchenne muscular dystrophy

Akihiro Taguchi; Shigenobu Nishiguchi; Masataka Shiozuka; Takao Nomoto; Mayuko Ina; Shouta Nojima; Ryoichi Matsuda; Yoshiaki Nonomura; Yoshiaki Kiso; Yuri Yamazaki; Fumika Yakushiji; Yoshio Hayashi

doi:10.1021/ml200245t

Negamycin analogue with readthrough-promoting activity as a potential drug candidate for Duchenne muscular dystrophy

Akihiro Taguchi, Shigenobu Nishiguchi, Masataka Shiozuka, Takao Nomoto, Mayuko Ina, Shouta Nojima, Ryoichi Matsuda, Yoshiaki Nonomura, Yoshiaki Kiso, Yuri Yamazaki, Fumika Yakushiji, Yoshio Hayashi

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

A series of (+)-negamycin 1 analogues were synthesized, and their readthrough-promoting activity was evaluated for nonsense mutations in Duchenne muscular dystrophy (DMD). A structure-activity relationship study indicated that 11b was the most potent drug candidate. Immunohistochemical analyses suggested that treatment with 11b restored dystrophin expression in mdx mice, a DMD mouse model. Furthermore, 11b decreased serum creatine kinase (CK) levels, an indicator of muscle fiber destruction. Most importantly, 11b demonstrated lower toxicity than 1, and thus, it could be a useful candidate for long-term treatment of DMD.

Original language	English
Pages (from-to)	118-122
Number of pages	5
Journal	ACS Medicinal Chemistry Letters
Volume	3
Issue number	2
DOIs	https://doi.org/10.1021/ml200245t
Publication status	Published - Feb 9 2012
Externally published	Yes

All Science Journal Classification (ASJC) codes

Biochemistry
Drug Discovery
Organic Chemistry

Access to Document

10.1021/ml200245t

Cite this

@article{68212576b5a74139a0044f73c97f6739,

title = "Negamycin analogue with readthrough-promoting activity as a potential drug candidate for Duchenne muscular dystrophy",

abstract = "A series of (+)-negamycin 1 analogues were synthesized, and their readthrough-promoting activity was evaluated for nonsense mutations in Duchenne muscular dystrophy (DMD). A structure-activity relationship study indicated that 11b was the most potent drug candidate. Immunohistochemical analyses suggested that treatment with 11b restored dystrophin expression in mdx mice, a DMD mouse model. Furthermore, 11b decreased serum creatine kinase (CK) levels, an indicator of muscle fiber destruction. Most importantly, 11b demonstrated lower toxicity than 1, and thus, it could be a useful candidate for long-term treatment of DMD.",

author = "Akihiro Taguchi and Shigenobu Nishiguchi and Masataka Shiozuka and Takao Nomoto and Mayuko Ina and Shouta Nojima and Ryoichi Matsuda and Yoshiaki Nonomura and Yoshiaki Kiso and Yuri Yamazaki and Fumika Yakushiji and Yoshio Hayashi",

year = "2012",

month = feb,

day = "9",

doi = "10.1021/ml200245t",

language = "English",

volume = "3",

pages = "118--122",

journal = "ACS Medicinal Chemistry Letters",

issn = "1948-5875",

publisher = "American Chemical Society",

number = "2",

}

TY - JOUR

T1 - Negamycin analogue with readthrough-promoting activity as a potential drug candidate for Duchenne muscular dystrophy

AU - Taguchi, Akihiro

AU - Nishiguchi, Shigenobu

AU - Shiozuka, Masataka

AU - Nomoto, Takao

AU - Ina, Mayuko

AU - Nojima, Shouta

AU - Matsuda, Ryoichi

AU - Nonomura, Yoshiaki

AU - Kiso, Yoshiaki

AU - Yamazaki, Yuri

AU - Yakushiji, Fumika

AU - Hayashi, Yoshio

PY - 2012/2/9

Y1 - 2012/2/9

N2 - A series of (+)-negamycin 1 analogues were synthesized, and their readthrough-promoting activity was evaluated for nonsense mutations in Duchenne muscular dystrophy (DMD). A structure-activity relationship study indicated that 11b was the most potent drug candidate. Immunohistochemical analyses suggested that treatment with 11b restored dystrophin expression in mdx mice, a DMD mouse model. Furthermore, 11b decreased serum creatine kinase (CK) levels, an indicator of muscle fiber destruction. Most importantly, 11b demonstrated lower toxicity than 1, and thus, it could be a useful candidate for long-term treatment of DMD.

AB - A series of (+)-negamycin 1 analogues were synthesized, and their readthrough-promoting activity was evaluated for nonsense mutations in Duchenne muscular dystrophy (DMD). A structure-activity relationship study indicated that 11b was the most potent drug candidate. Immunohistochemical analyses suggested that treatment with 11b restored dystrophin expression in mdx mice, a DMD mouse model. Furthermore, 11b decreased serum creatine kinase (CK) levels, an indicator of muscle fiber destruction. Most importantly, 11b demonstrated lower toxicity than 1, and thus, it could be a useful candidate for long-term treatment of DMD.

UR - http://www.scopus.com/inward/record.url?scp=84856913604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856913604&partnerID=8YFLogxK

U2 - 10.1021/ml200245t

DO - 10.1021/ml200245t

M3 - Article

AN - SCOPUS:84856913604

SN - 1948-5875

VL - 3

SP - 118

EP - 122

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

IS - 2

ER -

Negamycin analogue with readthrough-promoting activity as a potential drug candidate for Duchenne muscular dystrophy

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this